Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, marking a significant move in the PROTACs technology space.
Author: PharmaSignal News Desk
Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, enhancing its cancer treatment pipeline.
Agios Pyrukynd results show mixed outcomes in a crucial sickle cell study, affecting the drug’s commercial outlook.
Novo Nordisk Wegovy Pricing launches at $349 per month, months ahead of schedule, impacting the obesity drug market.
Scott Gottlieb joins UnitedHealth’s board, enhancing regulatory ties.
Sanofi AI ROI is about measurable improvements, not flashy demos, says CEO Paul Hudson.
Alkermes Avadel bid increases as the company aims to strengthen its position in the US market.
US CDC overdose warning highlights the risk of counterfeit medicines online, with fentanyl causing over 100,000 drug overdoses annually.
Arrowhead FDA approval for Redemplo marks its transition to a commercial-stage company, targeting a rare genetic disorder.
WuXi AppTec revenue growth highlights its resilience as US sales increase by 31.9% amid easing restrictions.